Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment

January 2023 in “ Annals of Dermatology ”

Hyunsun Park, Jung Eun Kim, Jee Woong Choi, Do Young ‍Kim, Yong Hyun Jang, Young Lee, Jiehyun Jeon, Hyun‐Tae Shin, Min Sung Kim, Jung Won Shin, Sung Bin Cho, Bark‐Lynn Lew, Gwang Seong Choi

alopecia areata systemic treatment

Studysummary This study produced updated treatment guidelines for severe alopecia areata patients in Korea, highlighting the efficacy of systemic corticosteroids, oral cyclosporine, and Janus kinase inhibitors.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on anndermatol.org →

Discuss this study in the Community →

Research cited in this study

42 / 42 results

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research Treatment of Pediatric Alopecia Areata: A Systematic Review

48 citations , April 2021 in “Journal of the American Academy of Dermatology”

This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.

research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

research Treatment of Alopecia Areata in Pre-Adolescent Children with Oral Tofacitinib: A Retrospective Study

26 citations , October 2020 in “Pediatric Dermatology”

This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.

Utility of Azathioprine, Methotrexate, and Cyclosporine as Steroid-Sparing Agents in Chronic Alopecia Areata: A Retrospective Study of Continuation Rates in 138 Patients

research Utility of Azathioprine, Methotrexate, and Cyclosporine as Steroid-Sparing Agents in Chronic Alopecia Areata: A Retrospective Study of Continuation Rates in 138 Patients

12 citations , August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.

research Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review

13 citations , April 2020 in “Dermatology and therapy”

This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.

research Italian Guidelines in Diagnosis and Treatment of Alopecia Areata

37 citations , December 2019 in “Giornale italiano di dermatologia e venereologia”

This Italian guideline discusses the diagnosis and treatment of alopecia areata but reports no new clinical trial results; the authors highlight the need for well-designed studies.

research Alopecia Universalis Treated with Simvastatin/Ezetimibe, Minoxidil, and Prednisolone in a 6-Year-Old Girl

1 citations , November 2019 in “International Journal of Dermatology”

This correspondence discusses the treatment of alopecia universalis in a 6-year-old girl using simvastatin/ezetimibe, minoxidil, and prednisolone, but it reports no new clinical findings.

research Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis

54 citations , September 2019 in “Journal of the European Academy of Dermatology and Venereology”

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

research Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate-to-Severe Alopecia Areata

10 citations , July 2019 in “Indian Journal of Dermatology”

This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.

research Cyclosporine for Moderate-to-Severe Alopecia Areata: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety

44 citations , April 2019 in “Journal of the American Academy of Dermatology”

This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations , February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

research Tofacitinib Therapy for Children with Severe Alopecia Areata

39 citations , January 2019 in “Journal of the American Academy of Dermatology”

In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.

research Treatment of Alopecia Areata: An Australian Expert Consensus Statement

95 citations , November 2018 in “Australasian journal of dermatology”

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

research Systemic Treatments for Alopecia Areata: A Systematic Review

41 citations , September 2018 in “Australasian journal of dermatology”

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

research Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children

40 citations , September 2018 in “Journal of the American Academy of Dermatology”

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

research Mesalazine in the Treatment of Extensive Alopecia Areata: A New Therapeutic Option?

10 citations , January 2018 in “International Journal of Trichology”

In this study, researchers retrospectively analyzed five children with extensive and refractory alopecia areata treated with mesalazine, observing complete hair regrowth in all patients without side effects, suggesting potential benefits of this treatment combination, though controlled studies are needed for confirmation.

research Alopecia Areata: Treatment Options and Efficacy

182 citations , December 2017 in “Journal of the American Academy of Dermatology”

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

research Prevalence of Pediatric Alopecia Areata Among 572,617 Dermatology Patients

28 citations , October 2017 in “Journal of the American Academy of Dermatology”

Pediatric alopecia areata is rare, affecting more girls than boys, and peaks at ages 9-12.

research Management of Alopecia Areata: Updates and Algorithmic Approach

47 citations , June 2017 in “Journal of dermatology”

This review highlights the diverse prognoses and limited long-term efficacy of current alopecia areata treatments, discussing existing and emerging therapies—including biologics—and proposing an algorithmic management approach based on specific disease characteristics.

research Methotrexate for the Treatment of Pediatric Alopecia Areata

22 citations , June 2017 in “Journal of dermatological treatment”

This case series observed that 57% of pediatric patients with alopecia areata experienced significant hair regrowth with methotrexate treatment, which was generally safe, although some results were inconclusive due to follow-up issues.

research High-Dose Pulsed Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata in Childhood

15 citations , May 2017 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

research Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis

49 citations , March 2017 in “Journal of the American Academy of Dermatology”

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

research Unsuccessful Treatment of Alopecia Areata with Simvastatin/Ezetimibe: Experience in 12 Patients

14 citations , January 2017 in “Skin appendage disorders”

This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.

research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents

139 citations , November 2016 in “Journal of the American Academy of Dermatology”

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

research Pulse Corticosteroid Therapy With Oral Dexamethasone for the Treatment of Adult Alopecia Totalis and Universalis

31 citations , April 2016 in “Journal of the American Academy of Dermatology”

Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.

research Methotrexate in Severe Childhood Alopecia Areata: Long-Term Follow-Up

25 citations , June 2015 in “Acta dermato-venereologica”

Methotrexate can help some kids with severe hair loss regrow hair.

Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design

research Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design

21 citations , January 2013 in “Annals of dermatology/Annals of Dermatology”

In this study, combination therapy with cyclosporine and PUVA for severe alopecia areata resulted in a majority of patients showing only fair to poor responses, though some improvements were noted.

research British Association of Dermatologists’ Guidelines for the Management of Alopecia Areata 2012

218 citations , April 2012 in “British Journal of Dermatology”

This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.

research Prognostic Factors in Methylprednisolone Pulse Therapy for Alopecia Areata

27 citations , May 2011 in “Journal of dermatology”

In this study, methylprednisolone pulse therapy was found to be effective for severe alopecia areata patients, especially those with a short disease duration or plurifocal type.

research Efficacy and Tolerability of Methotrexate in Severe Childhood Alopecia Areata

70 citations , April 2011 in “British journal of dermatology/British journal of dermatology, Supplement”

This retrospective study found that methotrexate had variable efficacy in treating severe alopecia areata in children, with successful hair regrowth observed in five out of thirteen assessable cases.

research Medium-Dose Prednisolone Pulse Therapy in Alopecia Areata

17 citations , November 2009 in “Dermato-endocrinology”

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

research Alefacept for Severe Alopecia Areata: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial

43 citations , November 2009 in “Archives of dermatology”

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

research Treatment of Persistent Alopecia Areata with Sulfasalazine

45 citations , July 2008 in “International Journal of Dermatology”

This study found that oral sulfasalazine led to varying hair regrowth outcomes in patients with persistent alopecia areata, with 56.3% showing moderate to good responses.

research Treatment of Severe Alopecia Areata: Combination Therapy Using Systemic Cyclosporine A with Low Dose Corticosteroids

8 citations , January 2008 in “Annals of Dermatology”

This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.

research A Comparison of the Efficacy, Relapse Rate, and Side Effects Among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata

97 citations , January 2006 in “Dermatology”

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

research Placebo-Controlled Oral Pulse Prednisolone Therapy in Alopecia Areata

141 citations , February 2005 in “Journal of the American Academy of Dermatology”

In this study, oral prednisolone pulse therapy led to significant hair regrowth in some patients with extensive alopecia areata, whereas no improvement was seen in the placebo group.

research Guidelines for the Management of Alopecia Areata

182 citations , October 2003 in “British Journal of Dermatology”

These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.

research Sulfasalazine for Alopecia Areata

62 citations , April 2002 in “Journal of the American Academy of Dermatology”

In this study, sulfasalazine treatment resulted in cosmetically acceptable hair regrowth in 23% of patients with severe alopecia areata in whom a response could be determined.